Download the meeting impression of this PACE symposium during Heart Failure 2018, which considered what recent outcome trials with glucose-lowering trials can tell us about us about optimal management of patients with HF and diabetes.

Prof. Zannad compared the clinical outcomes in trials of various novel classes of glucose-lowering drugs, to postulate what these findings may tell us about their mechanism of action, and how they can be benefitted from in the management of patients with HF and diabetes.

Prof. Sattar looked at the data of recent outcome trials to postulate how they might work to exert the observed clinical benefit. Altered hemodynamics likely importantly contribute to the benefits on HF outcomes.

Prof. Cowie reflected on what good care for heart failure patients with diabetes should entail, and concludes that minimal care for diabetes does not differ so much from minimal standard care in HF practice.

Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.

Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.

Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.

Slides as educational service to PACE members and meeting participants.

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants